Advertisement

Statin Controversies

Part of the Contemporary Cardiology book series (CONCARD)

Abstract

A Study to Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived Coronary atheroma burden (ASTEROID) trial showed that very-high-intensity statin therapy resulted in significant regression of atherosclerosis for all three prespecified measures of disease burden (1).

Keywords

Statin Therapy Cholesterol Ester Transfer Protein Multicenter Automatic Defibrillator Implantation Trial Percent Atheroma Volume Atheroma Regression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial. JAMA 2006;295:1556–1565.PubMedCrossRefGoogle Scholar
  2. 2.
    Blumenthal RS, Kapur NK. Canapotentstatinactuallyregresscoronaryatherosclerosis? JAMA 2006;295: 1583–1584.PubMedCrossRefGoogle Scholar
  3. 3.
    Ray KK, Cannon CP, Cairns R, et al. for the PROVE IT-TIMI 22 Investigators. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005;46:1417–1424.PubMedCrossRefGoogle Scholar
  4. 4.
    LaRosa JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–1435.PubMedCrossRefGoogle Scholar
  5. 5.
    Pedersen TR, Faergeman O, Kastelein JJP, et al. High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial. JAMA 2005;294:2437–2445.PubMedCrossRefGoogle Scholar
  6. 6.
    Graham DJ, Staffa JA, Shatin D, Andrade SE. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585–2590.PubMedCrossRefGoogle Scholar
  7. 7.
    Cannon CP. The IDEAL cholesterol: Lower is better. JAMA 2005;294:2492–2494.PubMedCrossRefGoogle Scholar
  8. 8.
    Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366: 1267–1278.PubMedCrossRefGoogle Scholar
  9. 9.
    Ramasubbu K, Mann DL. The emerging role of statins in the treatment of heart failure. J Am Coll Cardiol 2004;47:342–344.CrossRefGoogle Scholar
  10. 10.
    Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004;43:642–648.PubMedCrossRefGoogle Scholar
  11. 11.
    Vyas AK, Guo H, Moss AJ, et al. for the MADIT-II Research Group. Reduction in ventricular tachyarrhythmias with statins in the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006;47:769–773.PubMedCrossRefGoogle Scholar
  12. 12.
    Research Group. Coronary Drug Project: Clofibrate and niacin in coronary heart disease. JAMA 1975; 231:360.CrossRefGoogle Scholar
  13. 13.
    The Field Study Investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study). Lancet 2005;366:1849–1861.CrossRefGoogle Scholar
  14. 14.
    Barter PJ, Kastelein JJP. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006;47:492–499.PubMedCrossRefGoogle Scholar
  15. 15.
    Davidson MH, Maki K, Umporowicz D, Wheeler A, Rittershaus C, Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 2003;169:113–120.PubMedCrossRefGoogle Scholar

Suggested Reading

  1. Barter PJ, Kastelein JJP. Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease. J Am Coll Cardiol 2006;47:492–499.PubMedCrossRefGoogle Scholar
  2. Blumenthal RS, Kapur NK. Can apotent statin actually regress coronary atherosclerosis? JAMA 2006;295: 1583–1584.PubMedCrossRefGoogle Scholar
  3. Setoguchi S, Glynn RJ, Avorn J, et al. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation 2007;115:27–33.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc., Totowa, NJ 2007

Personalised recommendations